Isoniazide and rifampicin co-loaded microsphere sustained release preparation and preparation method thereof

A slow-release preparation and isoniazid technology, which is applied to medical preparations with non-active ingredients, medical preparations containing active ingredients, and pharmaceutical formulas, etc., can solve the problems of organic solvent residues, easy adhesion and aggregation of particles, and low yield

Pending Publication Date: 2021-11-26
QIQIHAR MEDICAL UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The technical effect of this patented method is that it allows creation of small particles with sizes ranging from 0.38-1µM (micrometers) up to 3.6-3. This can help improve their ability to deliver these types of medications specifically into areas where they could cause harm or even deteriorate health if taken by other methods such as injection.

Problems solved by technology

This patents describes different ways to deliver antibiotic agents (antimicroblasts), chemotherapeuces/immunomycins, steroids, etc., specifically towards tumors located deep inside organs like lung nodules. These treatments require long periods of hospitalization due to their side effects, including potential recurrence rates. To address these issues, controlled release systems containing both active ingredients and slow receptor dynamics may provide better control over dosings compared to current solutions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isoniazide and rifampicin co-loaded microsphere sustained release preparation and preparation method thereof
  • Isoniazide and rifampicin co-loaded microsphere sustained release preparation and preparation method thereof
  • Isoniazide and rifampicin co-loaded microsphere sustained release preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0031] Experimental example 1 In vitro analysis method experiment of isoniazid and rifampicin

[0032] Rifampicin and isoniazid UV spectrophotometry: After full-wavelength scanning, rifampicin has maximum absorption at 238 nm, 254 nm and 334 nm wavelength, and minimum absorption at 298 nm wavelength. Isoniazid has an absorption maximum at a wavelength of 262 nm. In the comprehensive analysis, 262 nm was used as the detection wavelength of rifampicin and isoniazid analysis methods.

[0033]HPLC detection methodology for rifampicin and isoniazid: Chromatographic column: Besil-C18 (5 μm, 4.6×250 mm), UV spectrophotometer detection wavelength: 262 nm, injection volume: 20 µL, column temperature: 25°C , flow rate: 1.0 mL / min, mobile phase A: disodium hydrogen phosphate solution (0.02 mol / L) and adjust the pH value to 4.0 with phosphoric acid, mobile phase B: methanol: acetonitrile (volume ratio 1:2). The volume ratio of mobile phase A and B was kept constant at 95:5 in the first ...

experiment example 2

[0034] Experimental example 2 Prescription optimization of PLGA microsphere preparation process

[0035] 1. Single factor investigation: According to the preparation method, select the ratio of phospholipids and cholesterol, the amount of phospholipids and cholesterol added, the rotational speed, the concentration of PVA in the water phase, the concentration of PLGA in the oil phase, the volume ratio of oil to water, voltage, receiving distance, injection speed, dosage, dosage The proportion and the proportion of dichloromethane and absolute ethanol in the oil phase are used as the influencing factors of microsphere quality control, and the single factor experiment is carried out with the average particle size and encapsulation efficiency as evaluation indicators. From the experimental results, it can be seen that the addition of phospholipid cholesterol is between 1.4% and 5.6%, the oil-water volume ratio is between 1:8 and 1:10, the receiving distance is between 10 and 15 cm,...

Embodiment 1

[0044] Co-loaded isoniazid and rifampicin lung targeting PLGA microsphere preparation, the preparation method is:

[0045] (1) The water phase is precisely weighed 26 mg of isoniazid and added to 0.5 mL of 1.4% PVA aqueous solution, and bathed in water at 40°C for 10 minutes;

[0046] (2) The oil phase is a mixed solution of precisely weighed rifampicin 26 mg, 7% PLGA (lactic acid-glycolic acid 75:25), phospholipid 60 mg and cholesterol 10 mg dissolved in 5 mL of dichloromethane and absolute ethanol , ultrasonication in a water bath for 5 min facilitates its dissolution;

[0047] (3) Add the water phase to the oil phase, mix, homogenize, and emulsify for 2 minutes with a hand-held homogenizer at 1000 rpm, and then draw it into a 5mL syringe;

[0048] (4) Place the syringe on the injection pump of the electrospinning machine, and choose a needle of 21 # , to establish a high-voltage electric field between the needle and the receiving device. After setting the voltage of 8 kV...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an isoniazide and rifampicin co-loaded microsphere sustained release preparation and a preparation method thereof, two antituberculous drugs, isoniazide and rifampicin, are jointly entrapped in PLGA microspheres by using an electrostatic fluid spraying technology, the average particle size of the microspheres meets the effective particle size of pulmonary administration, and the entrapment efficiency is high. A 15-day in-vitro drug release experiment shows that the cumulative drug release rate of the drug in the microspheres is 40%-60%, and the technical requirement of slow release is met. The local drug concentration of tuberculosis drugs in the lung can be effectively improved, the administration frequency is reduced, toxic and side effects are reduced, and the economic benefit ratio of the drugs is improved.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner QIQIHAR MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap